WebCompared to other companies in this collection, Lantheus is in a period of rapid growth owing to it being still a maturing company. Full year 2024 results saw a 119.9% increase in revenue to US$935.1M, lead largely by the success of PYLARIFY - their PSMA PET imaging agent - and the expansion of their Radiopharmaceutical Oncology pipeline. WebFeb 24, 2024 · PYLARIFY ® (piflufolastat F 18) Injection is a radioactive diagnostic agent indicated for positron emission tomography (PET) of prostate-specific membrane antigen (PSMA) positive lesions in men...
Lantheus Announces the First and Only FDA Cleared AI-Enabled …
WebNov 22, 2024 · Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable Suspension; PYLARIFY ®, a PSMA PET imaging... WebMar 29, 2024 · According to a statement from Lantheus, the firm believes that the recent approval of Novartis' radiopharmaceutical will increase demand for PSMA PET imaging. The company estimates that with Pluvicto on the market, PSMA PET imaging will increase by roughly 30,000 de novo scans per year, yielding a $1.1 billion market opportunity. excyte mini analyzer
PSMA Radiopharmaceutical Effective against Prostate Cancer
WebAt Lantheus, we're launching PYLARIFY, a PSMA-targeted PET imaging agent for prostate cancer. With my team of 9 account managers, we drive contracting, adoption and referrals for Pylarify through ... WebJun 4, 2024 · Lantheus, the developer of piflufolastat F 18, selected oncology provider GenesisCare to administer the first commercially available dose of piflufolastat F 18. 1 Piflufolastat F 18 was approved based on findings from the CONDOR and OSPREY studies. WebMay 27, 2024 · Lantheus provides a broad portfolio of products, including the echocardiography agent DEFINITY ® Vial for (Perflutren Lipid Microsphere) Injectable … herbarium jcb